The Medical Advisor

Introduction When facing aggressive malignancies like liver cancer and cholangiocarcinoma (bile duct cancer), the traditional oncological toolkit can sometimes feel frustratingly limited. However, a growing wave of interest is focusing on drug repurposing—the practice of using well-established, existing medications for entirely new therapeutic targets. This compilation highlights an emerging series of 9 patient case reports exploring the off-label use of antiparasitic agents, specifically ivermectin, fenbendazole, and mebendazole. While these compounds are traditionally known for clearing parasites, preclinical research suggests they may also strike at the heart of cancer cells by disrupting microtubules (the structural scaffolding cells need to divide) and blocking major cellular growth pathways like Wnt/β-catenin. Divided into 4 liver cancer cases and 5 bile duct cancer cases, these real-world updates—headlined by clinical accounts shared by figures like Dr. William Makis—document st...